Tempest Therapeutics Stock Market Outlook
| TPST Stock | USD 2.36 0.05 2.16% |
Slightly above 55% of Tempest Therapeutics' private investors are presently thinking to get in. The analysis of the overall investor sentiment regarding Tempest Therapeutics suggests that some traders are interested. Tempest Therapeutics' investing sentiment can be driven by a variety of factors including economic data, Tempest Therapeutics' earnings reports, geopolitical events, and overall market trends.
Comfort Level 55
Impartial
Panic | Confidence |
Today, several news technology companies offer sentiment data to assist traders in manufacturing news sentiment indicators for investment decisions. We partner with these technology firms in helping retail investors build forecasting models that use Tempest Therapeutics' input sentiment indicators derived from textual data and news published on major financial information outlets and social sites. These indicators can be used to analyze time-dependent numerical information representing public perception toward Tempest Therapeutics.
News SentimentBullish | Hype SentimentBearish | Insider SentimentAcquiring |
Given the investment horizon of 90 days and your below-average risk tolerance, our recommendation regarding Tempest Therapeutics is 'Strong Sell'. A buy or sell recommendation is an automated directive regarding whether to purchase or sell Tempest Therapeutics given historical horizon and risk tolerance. When we issue a 'buy' or 'sell' recommendation for Tempest Therapeutics, the advice is generated through an automated system that utilizes algorithms and statistical models.
Execute Tempest Therapeutics Advice
The Tempest recommendation should be used to complement the investment advice compiled from the current analysts' consensus on Tempest Therapeutics. Macroaxis does not own or have any residual interests in Tempest Therapeutics or other equities on which the buy-or-sell advice is provided. Please provide your input below to execute Tempest Therapeutics' advice using the current market data and latest reported fundamentals.
Time Horizon
Risk Tolerance
 |  |
Strong Sell
Market Performance | Weakest | Details | |
Volatility | Very risky | Details | |
Hype Condition | Over hyped | Details | |
Current Valuation | Undervalued | Details | |
Odds Of Distress | Risky | Details | |
Economic Sensitivity | Follows the market closely | Details | |
Investor Sentiment | Impartial | Details | |
Analyst Consensus | Hold | Details | |
Financial Strenth (F Score) | Frail | Details | |
Financial Leverage | Not Rated | Details | |
Reporting Quality (M-Score) | Unlikely Manipulator | Details |
For the selected time horizon Tempest Therapeutics has a Mean Deviation of 4.76, Standard Deviation of 8.58 and Variance of 73.6We provide advice to complement the current expert consensus on Tempest Therapeutics. Our dynamic recommendation engine harnesses a multidimensional algorithm to analyze the firm's potential to grow using all technical and fundamental data available at the time. To make sure Tempest Therapeutics is not overpriced, please validate all Tempest Therapeutics fundamentals, including its cash per share, as well as the relationship between the short ratio and total asset . Please also confirm Tempest Therapeutics price to earning to double-check your buy or sell decision is consistent with all fundamental data available and that the company can sustain itself in the current economic cycle.
Tempest Therapeutics Trading Alerts and Improvement Suggestions
| Tempest Therapeutics generated a negative expected return over the last 90 days | |
| Tempest Therapeutics has high historical volatility and very poor performance | |
| Tempest Therapeutics has a very high chance of going through financial distress in the upcoming years | |
| Net Loss for the year was (41.84 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Tempest Therapeutics currently holds about 51.62 M in cash with (33.03 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 4.95, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Tempest Therapeutics has a frail financial position based on the latest SEC disclosures | |
| Roughly 37.0% of the company outstanding shares are owned by corporate insiders | |
| Latest headline from news.google.com: Tempest Therapeutics closes CAR T acquisition and names new CEO - stocktitan.net |
Tempest Therapeutics Returns Distribution Density
The distribution of Tempest Therapeutics' historical returns is an attempt to chart the uncertainty of Tempest Therapeutics' future price movements. The chart of the probability distribution of Tempest Therapeutics daily returns describes the distribution of returns around its average expected value. We use Tempest Therapeutics price's Value At Risk and its Upside Potential as a relative measure of the distribution. The graph of the distribution of Tempest Therapeutics returns is essential to provide solid investment analysis for Tempest Therapeutics.
| Mean Return | -1.68 | Value At Risk | -9.56 | Potential Upside | 7.62 | Standard Deviation | 8.58 |
Return Density |
| Distribution |
Investment risk management requires an estimate of the probability of extreme price changes. Therefore, the correct representation of the distribution of Tempest Therapeutics historical returns presented in an easy-to-digest graphical form helps investors and money managers understand the risk-reward trade-off of different investement strategies.
Tempest Stock Institutional Investors
The Tempest Therapeutics' institutional investors refer to entities that pool money to purchase Tempest Therapeutics' securities or originate loans. These institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds.
| Shares | Atlantic Trust Group, Llc | 2025-06-30 | 260 | Sbi Securities Co Ltd | 2025-06-30 | 56.0 | Bank Of America Corp | 2025-06-30 | 33.0 | Parallel Advisors, Llc | 2025-06-30 | 18.0 | Bnp Paribas Arbitrage, Sa | 2025-06-30 | 3.0 | Jane Street Group Llc | 2025-03-31 | 0.0 | Tower Research Capital Llc | 2025-03-31 | 0.0 | Global Retirement Partners, Llc. | 2025-06-30 | 0.0 | Millennium Management Llc | 2025-03-31 | 0.0 | Sabby Management Llc | 2025-06-30 | 276.6 K | Versant Venture Management Llc | 2025-06-30 | 269.8 K |
Tempest Therapeutics Cash Flow Accounts
| 2021 | 2022 | 2023 | 2024 | 2025 | 2026 (projected) | ||
| Change In Cash | 33.0M | (20.2M) | 8.1M | (9.0M) | (8.1M) | (7.7M) | |
| Free Cash Flow | (26.1M) | (31.6M) | (27.5M) | (33.5M) | (30.1M) | (31.6M) | |
| Depreciation | 374K | 638K | 381K | 389K | 350.1K | 563.3K | |
| Other Non Cash Items | 1.5M | 1.6M | 1.9M | 1.5M | 1.4M | 1.3M | |
| Capital Expenditures | 135K | 562K | 170K | 435K | 391.5K | 371.9K | |
| Net Income | (28.3M) | (35.7M) | (29.5M) | (41.8M) | (48.1M) | (50.5M) | |
| End Period Cash Flow | 51.8M | 31.6M | 39.7M | 30.7M | 35.3M | 38.4M | |
| Investments | (97K) | (562K) | (519K) | (435K) | (391.5K) | (411.1K) |
Tempest Therapeutics Greeks
Most traded equities are subject to two types of risk - systematic (i.e., market) and unsystematic (i.e., nonmarket or company-specific) risk. Unsystematic risk is the risk that events specific to Tempest Therapeutics or Biotechnology sector will adversely affect the stock's price. This type of risk can be diversified away by owning several different stocks in different industries whose stock prices have shown a small correlation to each other. On the other hand, systematic risk is the risk that Tempest Therapeutics' price will be affected by overall stock market movements and cannot be diversified away. So, no matter how many positions you have, you cannot eliminate market risk. However, you can measure a Tempest stock's historical response to market movements and buy it if you are comfortable with its volatility direction. Beta and standard deviation are two commonly used measures to help you make the right decision.
α | Alpha over Dow Jones | -1.73 | |
β | Beta against Dow Jones | 0.76 | |
σ | Overall volatility | 8.75 | |
Ir | Information ratio | -0.2 |
Tempest Therapeutics Volatility Alert
Tempest Therapeutics is displaying above-average volatility over the selected time horizon. Understanding different market volatility trends often help investors to time the market. Properly using volatility indicators enable traders to measure Tempest Therapeutics' stock risk against market volatility during both bullish and bearish trends. The higher level of volatility that comes with bear markets can directly impact Tempest Therapeutics' stock price while adding stress to investors as they watch their shares' value plummet. This usually forces investors to rebalance their portfolios by buying different financial instruments as prices fall.Tempest Therapeutics Fundamentals Vs Peers
Comparing Tempest Therapeutics' fundamentals to the average values of its peers is one of the most widely used and accepted methods of equity analyses. It helps to analyze Tempest Therapeutics' direct or indirect competition across all of the common fundamentals between Tempest Therapeutics and the related equities. This way, we can detect undervalued stocks with similar characteristics as Tempest Therapeutics or determine the stocks which would be an excellent addition to an existing portfolio. Peer analysis of Tempest Therapeutics' fundamental indicators could also be used in its relative valuation, which is a method of valuing Tempest Therapeutics by comparing valuation metrics with those of similar companies.
| Better Than Average | Worse Than Average | Compare Tempest Therapeutics to competition |
| Fundamentals | Tempest Therapeutics | Peer Average |
| Return On Equity | -4.05 | -0.31 |
| Return On Asset | -0.89 | -0.14 |
| Current Valuation | 12.47 M | 16.62 B |
| Shares Outstanding | 4.93 M | 571.82 M |
| Shares Owned By Insiders | 36.69 % | 10.09 % |
| Shares Owned By Institutions | 8.22 % | 39.21 % |
| Number Of Shares Shorted | 144.51 K | 4.71 M |
| Price To Earning | 0.23 X | 28.72 X |
| Price To Book | 1.82 X | 9.51 X |
| EBITDA | (40.14 M) | 3.9 B |
| Net Income | (41.84 M) | 570.98 M |
| Cash And Equivalents | 51.62 M | 2.7 B |
| Cash Per Share | 4.95 X | 5.01 X |
| Total Debt | 15.37 M | 5.32 B |
| Debt To Equity | 0.49 % | 48.70 % |
| Current Ratio | 3.05 X | 2.16 X |
| Book Value Per Share | 1.43 X | 1.93 K |
| Cash Flow From Operations | (33.03 M) | 971.22 M |
| Short Ratio | 1.66 X | 4.00 X |
| Earnings Per Share | (9.73) X | 3.12 X |
| Target Price | 11.0 | |
| Number Of Employees | 24 | 18.84 K |
| Beta | -2.24 | -0.15 |
| Market Capitalization | 11.63 M | 19.03 B |
| Total Asset | 41.49 M | 29.47 B |
| Retained Earnings | (207.11 M) | 9.33 B |
| Working Capital | 17.25 M | 1.48 B |
| Net Asset | 41.49 M |
Note: Insider Trading [view details]
Tempest Therapeutics Market Momentum
Traders often use several daily momentume indicators to supplement a more traditional technical analysis when analyzing securities such as Tempest . With many different options, investors must choose the best indicators for them and familiarize themselves with how they work. We suggest combining traditional momentum indicators with more near-term forms of technical analysis such as Accumulation Distribution or Daily Balance Of Power. With their quantitative nature, daily value technical indicators can also be incorporated into your automated trading systems.
About Tempest Therapeutics Buy or Sell Advice
When is the right time to buy or sell Tempest Therapeutics? Buying financial instruments such as Tempest Stock isn't very hard. However, what challenging for most investors is doing it at the right time to beat the market. Proper market timing is something most people cannot do without sophisticated tools, which help to isolate the right opportunities. Macroaxis provides hands-on modules to deliver winning trades and diversify your portfolios on a daily basis. Most of our advising modules are very easy to use and apply.
Please read more on our stock advisor page.
Use Investing Ideas to Build Portfolios
In addition to having Tempest Therapeutics in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run High Dividend Yield ETFs Thematic Idea Now
High Dividend Yield ETFs
ETF themes focus on helping investors to gain exposure to a broad range of assets, diversify, and lower overall costs. The High Dividend Yield ETFs theme has 111 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize High Dividend Yield ETFs Theme or any other thematic opportunities.
| View All Next | Launch |
Additional Tools for Tempest Stock Analysis
When running Tempest Therapeutics' price analysis, check to measure Tempest Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Tempest Therapeutics is operating at the current time. Most of Tempest Therapeutics' value examination focuses on studying past and present price action to predict the probability of Tempest Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Tempest Therapeutics' price. Additionally, you may evaluate how the addition of Tempest Therapeutics to your portfolios can decrease your overall portfolio volatility.